摘要
目的观察吉西他滨单药一线治疗老年晚期非小细胞的有效性和安全性。方法对50例晚期非小细胞肺癌患者，应用吉西他滨110g／m2，静脉注入，d1，8，15，停药3周后重复。至少接受2个周期的化疗。结果50例均可评价疗效，有效率为45．2％，临床受益率89．1％。结论主要不良反应为粒细胞减少，无治疗相关性死亡。
Objective To evaluate the efficacy and toxicity of China2made gemcitabine （GEM） in the first line monotherapy of the elderly patients with advanced NSCLC. Method 50 cases of advanced NSCLC were treated with GEM 1 000 mg/iv drip on dl, d8 and d15, and 3 weeks as a cycle. All of the patients received the chemotherapy at least for two cycles. Results The total objective response rate was 45.2 %. The clinical benefit rate was 89.1%. Conclusion The main adverse effect was granulocytopenia. There was no treatment related death.
关键词
吉西他滨
非小细胞肺癌
药物疗法
gemcitabine, non small cell lung cancer, Medication and dosage
